CN1241656C - Aretificial nerve canula material of slow operating complex type poly lactic acid and preparation method - Google Patents
Aretificial nerve canula material of slow operating complex type poly lactic acid and preparation method Download PDFInfo
- Publication number
- CN1241656C CN1241656C CN 200410012846 CN200410012846A CN1241656C CN 1241656 C CN1241656 C CN 1241656C CN 200410012846 CN200410012846 CN 200410012846 CN 200410012846 A CN200410012846 A CN 200410012846A CN 1241656 C CN1241656 C CN 1241656C
- Authority
- CN
- China
- Prior art keywords
- nerve
- composite
- catheter
- polylactic acid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The present invention relates to a composite catheter material for slowly releasing artificial nerves and recovering nerve coloboma of human bodies and a preparation method thereof. The catheter material is made from the composite material of biologic absorbable polylactic acid, nanometer hydroxyapatite powder and freeze-drying powder of nerve growth factors (NGF) for inducing the growth of the nerves. The preparation method comprises the steps that firstly, the polylactic acid is dissolved in an organic solvent; secondly, the hydroxyapatite powder and the freeze-drying powder of NGF are added to the organic solvent and are dispersed in an ultrasonic mode; then, a composite nerve catheter provided with micropores is produced by a solvent volatilization method, the inner diameter of the composite nerve catheter is from 2.0 to 3.0mm, the wall thickness of the composite nerve catheter is from 0.1 to 0.3mm, and the length of the composite nerve catheter is from 10 to 15mm. The composite nerve catheter has the favorable biocompatibility and histocompatibility; the composite nerve catheter not only can provide a reliable hollow channel for the regeneration of the nerves, but also can be free from the interference of outer fiber tissues; the materials are gradually degraded in the human bodies in company with the recovery and the growth of the nerves; the repairing effect approximates to that of autologous neural transplantation.
Description
Technical Field
The invention relates to a composite slow-release artificial nerve conduit material for repairing and regenerating human nerve injury and a preparation technology thereof.
Background
Peripheral nerve injuries and defects are common in clinic, and the treatment effect is not satisfactory so far. How to improve the curative effect is still an important issue to be further researched and solved.
The mainproblems affecting nerve repair and regeneration are limited source of transplanted nerves, regional injury, slow nerve regeneration speed, poor regeneration quality and the like. There have been many previous studies of nerve substitutes, including autologous blood vessels, muscles, tendons, fascia, and synthetic, nonabsorbable and absorbable nerve bridging catheters. The materials and the methods achieve different treatment effects in animal experiments, and some materials are reported to be used in clinical research. However, the therapeutic effect is still unsatisfactory in general. The nonabsorbable artificial synthetic nerve conduit has the defects of continuous foreign body reaction, nerve compression by the conduit wall, need of re-operation and the like, and the absorbable synthetic conduit can be degraded in vivo, so that the defects can be avoided. In order to promote nerve regeneration, a plurality of nutrition factors for promoting nerve regeneration have been studied, wherein the function of Nerve Growth Factor (NGF) is more certain, and the research is more intensive. However, in animal experiments and clinical work, local one-time or multiple-time administration is adopted, or systemic multiple-time administration is adopted, the administration method is complicated, and the effect can not be fully exerted.
The ideal nerve conduit material should have biodegradability, permeability and low cytotoxicity. Materials for nerve conduits include porous stainless steel, elastic hydrogel, silicone tube, polyacrylic acid, polyethylene, etc., of which silicone tube is the most studied and has been considered as the most helpful material in nerve regeneration research. However, these materials are permanent and remain in place as foreign bodies after implantation in the body, which can lead to delayed recovery of nerve function and often require secondary surgical removal. In response to this drawback, in recent years, researchers have been working on the development of biodegradable polymeric materials, such as polyglycolic acid, polylactic acid, copolymers of lactic acid and glycolide, collagen, and the like. Examples of neurotrophic factors that promote nerve regeneration include Nerve Growth Factor (NGF), ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BDNF), and the like.
At present, no report of a nerve conduit prepared by using a multi-top composite material such as polylactic acid, nano hydroxyapatite, nerve growth factor and the like is found in domestic and foreign documents.
Disclosure of Invention
The invention aims to provide an artificial material for repairing nerve injury and a preparation method thereof. The material is an absorbable and controllable release material, and can exist in a transplantation part in vivo for a long enough time to protect regenerated nerves and a local microenvironment for nerve regeneration; the material is gradually degraded along with the regeneration of nerves so as to be completely absorbed and metabolized by the organism without being taken out again by operation, and has good permeability and can induce the growth of nerves.
In order to achieve the purpose, the invention screens nerve nutritional factors such as NGF and the like, and uses bioabsorbable polylactic acid (PDLLA) as a carrier material to prepare the composite artificial nerve conduit, which is used for repairing peripheral nerve injury and defect, promoting nerve regeneration and improving the nerve repairing effect.
The absorbable and controllable release nerve conduit material is a composite slow-release artificial material and consists of bioabsorbable polylactic acid (PDLLA), nano hydroxyapatite powder capable of adjusting the pH value of an implanted part and increasing the biological activity of the material and Nerve Growth Factor (NGF) powder for inducing nerve growth, wherein the polylactic acid accounts for 95-99 wt%, the nano hydroxyapatite powder accounts for 1-5 wt%, the NGF powder accounts for 0.1-1.0 wt% of the total mass of the two components, the weight average molecular weight of the polylactic acid is 3-10 ten thousand, the average particle size of the nano hydroxyapatite powder is 80-110 nm, and the NGF is freeze-dried powder.
The nerve conduit material is a composite conduit with an inner diameter of 2.0-3.0 mm, a wall thickness of 0.1-0.3mm, a length of 10-15 mm and micropores.
The preparation method of the composite conduit comprises the following steps:
(1) weighing polylactic acid and nano hydroxyapatite according to a set mass ratio, dissolving the polylactic acid and the nano hydroxyapatite in an organic solvent ethyl acetate or acetone, and performing ultrasonic dispersion;
(2) adding NGF freeze-dried powder with a set mass ratio, and performing ultrasonic dispersion;
(3) a solvent evaporation method is used for preparing the compound conduit with the inner diameter of 2.0-3.0 mm, the wall thickness of 0.1-0.3mm and the length of 10-15 mm and provided with micropores.
The preparation of polylactic acid used in the invention utilizes lactide ring-opening polymerization method to prepare PDLLA from D, L-lactic acid, and the steps are as follows:
1. selecting 85 wt% of D, L-lactic acid as a basic raw material, using anhydrous zinc oxide as a catalyst, heating to 130 ℃, distilling water under reduced pressure, rapidly heating to 230 ℃, distilling under reduced pressure, washing distilled fraction with ethyl acetate, and recrystallizing to obtain pure D, L-lactide;
2. ring-opening polymerization of D, L-lactide: and (2) weighing the D, L-lactide obtained in the step (1), placing the D, L-lactide in a clean ampere bottle, injecting a trichloromethane solution of stannous octoate with the mass of 0.3% of that of the D, L-lactide as an initiator, vacuumizing the ampere bottle by using a mechanical vacuum pump to gradually volatilize a solvent in the initiator, fusing and sealing the ampere bottle, placing the ampere bottle in an oil bath at the temperature of 130-160 ℃, and polymerizing for 4-48 hours to obtain the polylactic acid with the weight average molecular weight of 3-10 ten thousand.
The preparation of the nano hydroxyapatite powder used by the invention adopts a uniform precipitation method, and comprises the following steps:
(1) using calcium hydroxide (Ca (OH)2) And excess phosphoric acid (H)3PO4) Reacting to prepare hydrated calcium dihydrogen phosphate (Ca (H)2PO4)2·H2O)；
(2) Slowly adding calcium hydroxide and the hydrated calcium dihydrogen phosphate prepared in the step (1) into the mixture, mixing, and adding a stabilizerHeparin sodium reacts under the conditions of stirring and ultrasonic dispersion to quickly and uniformly nucleate hydroxyapatite to generate nano hydroxyapatite (Ca)10(PO4)6(OH)2)，。
The prepared catheter sample is placed in a phosphoric acid buffer solution, the swelling property and the degradability of the catheter are measured, and the shape, the pore size and the distribution of the catheter are observed by using a Nigri S-450 type scanning electron microscope.
The invention carries out in vitro simulation experiment on the degradation performance, the release rate of neurotrophic factors, influencing factors and the like of the prepared slow release catheter;
the invention artificially causes 0.5-1.0 cm of nerve defects of a white rat, the composite catheter is used for carrying out a functional test of the slow release catheter, and the performance and the function of the composite catheter are evaluated through 3-month experiments and test analysis.
Drawings
FIG. 1 is a process diagram for preparing a composite polylactic acid sustained-release artificial nerve conduit
FIG. 2 photograph of composite sustained-release catheter product
FIG. 3 is a photograph showing the micro-morphology of the composite sustained-release catheter
The preparation process of the compound polylactic acid slow-release artificial nerve conduit shown in the figure 1 comprises the following steps: preparing D, L-lactide by taking a monomer D, L-lactic acid as a raw material in the presence of an anhydrous zinc oxide catalyst, and then carrying out ring-opening polymerization on the D, L-lactide by taking a trichloromethane solution of stannous octoate as an initiator to prepare polylactic acid with the weight-average molecular weight of 3-10 ten thousand; selecting several different polypeptides, and screening nerve growth factor NGF with high biological activity through in vitro simulation activity research; adding nano hydroxyapatite powder for compounding, compounding by an ultrasonic dispersion method to obtain a uniform complex, preparing a slow release catheter by a solvent volatilization method, and testing and characterizing the structure and the performance of the catheter.
Detailed Description
Example 1
1. Preparation of polylactic acid
Adopts an indirect method to polymerize and dehydrate lactic acid and ring-opening and polymerize lactide into PDLLA, and has the following main chemical reaction processes:
the method mainly comprises the following steps:
(1) preparation of lactide
D, L-lactic acid with the content of 85 wt% is selected as a basic raw material, anhydrous zinc oxide is selected as a catalyst, the heating is carried out until the temperature is raised to 130 ℃, and water in the D, L-lactic acid is evaporated by a water pump under reduced pressure. Then quickly raising the temperature to 230 ℃, distilling the mixture by using an oil pump under reduced pressure, washing the distilled fraction by using ethyl acetate and recrystallizing to obtain pure D, L-lactide.
(2) Ring opening polymerization of D, L-lactide
Weighing a proper amount of D, L-lactide obtained in the step (1), putting the D, L-lactide into a clean ampere bottle, and then injecting a trichloromethane solution of stannous octoate which is 0.3 percent of the mass of the D, L-lactide as an initiator. And (3) vacuumizing by using a mechanical vacuum pump, gradually volatilizing the solvent in the initiator, fusing and sealing an ampere bottle by using an alcohol blast burner, placing the ampere bottle in an oil bath at the temperature of 130-160 ℃, and polymerizing for 4-48 hours to obtain the PDLLA with the weight-average molecular weight of 3-10 ten thousand.
2. Preparation of nano hydroxyapatite powder
Hydroxyapatite Sol (HAp-Sol) close to a monodisperse system is prepared by adopting a uniform precipitation method.
(1) Using calcium hydroxide (Ca (OH)2) And excess phosphoric acid (H)3PO4) Reacting to prepare hydrated calcium dihydrogen phosphate (Ca (H)2PO4)2·H2O)；
(2) With Ca (OH)2And Ca (H)2PO4)2·H2O and heparin sodium (as stabilizer), and reacting under stirring and ultrasonic dispersing conditions to generate hydroxyapatite (Ca)10(PO4)6(OH)2)。
The main reaction chemical equation is as follows:
during the preparation process, the excessive acid in the reaction process is controlled to prepare Ca (H)2PO4)2·H2And O. Control of Ca (H)2PO4)2·H2O and Ca (OH)2The concentration of (2) is that the product of the calcium ion concentration and the phosphate ion concentration exceeds the HAp solubility product, the calcium ion concentration and the phosphate ion concentration are slowly added and mixed, and the mixture is stirred to quickly and uniformly nucleate HAp in a short time to obtain nearly monodisperse hydroxyapatite with the average particle size of 80-110 nm.
3. Preparation of composite nerve conduit
(1) Preparation of composite catheters
38.8 g of PDLLA and 1.2 g of nano hydroxyapatite powder are weighed, dissolved in ethyl acetate and dispersed by ultrasonic waves. Then 0.04 g of NGF freeze-dried powder is added, and ultrasonic dispersion is carried out. A solvent evaporation method is used for preparing a compound conduit with micropores and an inner diameter of 2.0-3.0 mm, a wall thickness of 0.1-0.3mm and a length of 10-15 mm, and the compound conduit is shown in figure 2.
Weighing and calculating by using an electronic balance, wherein each catheter contains 450 mu of NGF (mu is a metering unit of nerve growth factor), in vitro experiments are carried out by placing a sample in a phosphoric acid buffer solution, measuring the swelling property and the degradability of the catheter and observing the appearance of the catheter by using a Nigri S-450 type scanning electron microscope, and the appearance before implantation of the catheter is shown in figure 3.
The uniform and interconnected porosity distribution on the surface of the conduit can be seen in fig. 3. After being implanted into a body, the material is degraded and the pores are enlarged along with the time. In-vitro experiment observation shows that the material swells in 15 days, the appearance is complete in 2 months, and the change of the pH value of the solution is slight.
4. Animal experiment with composite catheter
Healthy adult male SD rats 45 were divided into a group a and B, C. The group A is taken from the trunk of the somatic nerve, the group B is a pure PDLLA catheter, the group C is a composite catheter, and the operation is carried out under a microscope. The experimental effect of the material was evaluated by observation, electrical property measurement, histological examination, image analysis, and the like.
Electrophysiological examination revealed that A, B, C groups all were able to measure nerve conduction velocity and that the regenerated nerve had grown and was severed through the defect.
Histological examination showed that 3 months after the observation with a light microscope, the regenerated adventitia of group a and group C was intact, the number of nerve fibers in group C was large, the size was uniform, myelin was thick, the maturation was good, and the nerve was split into the tracts. While the group B has many blood vessels and fibrous connective tissues and disorganized nerve arrangement.
And (3) observing by a transmission electron microscope, wherein the groups A and C have more regenerated myelinated fibers, complete myelin sheaths, compact arrangement of lamina layers and lamina layers, close adjacent axon membranes and myelin sheaths, and good myelination. And the B group has less regenerated pulp fibers and is sparsely arranged.
The results of example 1 show that the composite nerve conduit has good biocompatibility and histocompatibility, not only can provide a reliable hollow pipeline for nerve regeneration without being interfered by external fibrous tissues, but also can gradually degrade materials in vivo along with the repair and growth of nerves. The repairing effect is similar to that of autologous nerve transplantation.
Claims (2)
1. The composite slow-release artificial nerve conduit material is characterized by consisting of 95-99 wt% of polylactic acid, 1-5 wt% of nano hydroxyapatite powder and 0.1-1.0 wt% of nerve growth factor NGF powder for inducing nerve growth, wherein the polylactic acid has the weight-average molecular weight of 3-10 ten thousand, the nano hydroxyapatite powder has the average particle size of 80-110 nm, the NGF is freeze-dried powder, and the nerve conduit material is a nerve conduit material with the inner diameter of 2.0-3.0 mm, the wall thickness of more than or equal to 0.1mm and less than 0.3mm, the length of 10-15 mm and micropores.
2. The preparation method of the composite slow-release artificialnerve conduit material of claim 1, which is characterized by comprising the following steps of:
(1) weighing polylactic acid and nano hydroxyapatite powder according to a set mass ratio, dissolving the polylactic acid and the nano hydroxyapatite powder in an organic solvent ethyl acetate or acetone, and performing ultrasonic dispersion;
(2) adding NGF freeze-dried powder with a set mass ratio, and performing ultrasonic dispersion;
(3) the composite conduit with the inner diameter of 2.0-3.0 mm, the wall thickness of more than or equal to 0.1mm and less than 0.3mm, the length of 10-15 mm and micropores is prepared by a solvent volatilization method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410012846 CN1241656C (en) | 2004-03-16 | 2004-03-16 | Aretificial nerve canula material of slow operating complex type poly lactic acid and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410012846 CN1241656C (en) | 2004-03-16 | 2004-03-16 | Aretificial nerve canula material of slow operating complex type poly lactic acid and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562383A CN1562383A (en) | 2005-01-12 |
| CN1241656C true CN1241656C (en) | 2006-02-15 |
Family
ID=34478007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410012846 Expired - Fee Related CN1241656C (en) | 2004-03-16 | 2004-03-16 | Aretificial nerve canula material of slow operating complex type poly lactic acid and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1241656C (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102028967B (en) * | 2010-11-19 | 2014-05-07 | 无锡中科光远生物材料有限公司 | Method for manufacturing micro-pipeline stent with nano structure on inner wall |
| CN104109684B (en) * | 2014-06-19 | 2017-02-22 | 中山大学附属第一医院 | Gene transfer material of functionalized nano hydroxyapatite and preparation method and application thereof |
| CN104327293B (en) * | 2014-11-21 | 2017-03-29 | 武汉理工大学 | Composite film material based on polymer P RGD and preparation method thereof |
| CN104645409B (en) * | 2014-12-29 | 2017-06-23 | 东莞颠覆产品设计有限公司 | A kind of PLA Nerve Scaffold and preparation method thereof |
| CN104587526B (en) * | 2014-12-29 | 2017-06-23 | 东莞颠覆产品设计有限公司 | A kind of collagen hydroxyapatite Nerve Scaffold and preparation method thereof |
| CN104524628B (en) * | 2014-12-29 | 2016-11-02 | 东莞颠覆产品设计有限公司 | A kind of hydroxyapatite Nerve Scaffold and preparation method thereof |
| CN107118200B (en) * | 2016-02-24 | 2020-02-28 | 香港纺织及成衣研发中心有限公司 | Method for catalytically synthesizing lactide by using lactic acid |
| CN107412857B (en) * | 2017-07-26 | 2020-02-18 | 武汉理工大学 | Polycaprolactone/chitosan/hydroxyapatite composite catheter stent and preparation method thereof |
| CN111317867A (en) * | 2020-02-06 | 2020-06-23 | 清华大学 | Nerve conduit and preparation method thereof |
| CN112957536A (en) * | 2021-03-23 | 2021-06-15 | 潍坊奥精医学研究有限公司 | Peripheral nerve regeneration and repair material and preparation method thereof |
-
2004
- 2004-03-16 CN CN 200410012846 patent/CN1241656C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1562383A (en) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220160935A1 (en) | Chitosan Nanofiber Compositions, Compositions Comprising Modified Chitosan, and Methods of Use | |
| CN113679888B (en) | Photo-curing molding composite hydrogel matrix precursor, preparation method thereof and stent with same | |
| JP4644374B2 (en) | Poly (propylene fumarate) crosslinked with poly (ethylene glycol) | |
| CN109568671B (en) | 3D bone repair scaffold with hydrogel loaded with cells and preparation method thereof | |
| Zhang et al. | Preparation of chitosan/hydroxyapatite guided membrane used for periodontal tissue regeneration | |
| CN1241656C (en) | Aretificial nerve canula material of slow operating complex type poly lactic acid and preparation method | |
| CN110408058B (en) | Halloysite composite hydrogel for promoting bone defect repair and preparation method and application thereof | |
| Gursel et al. | Synthesis and mechanical properties of interpenetrating networks of polyhydroxybutyrate-co-hydroxyvalerate and polyhydroxyethyl methacrylate | |
| CN106860915B (en) | Mineralized collagen bionic bone repair material modified by hyaluronic acid oligosaccharide and preparation method thereof | |
| Chłopek et al. | The influence of the environment on the degradation of polylactides and their composites | |
| KR102316879B1 (en) | Scaffold for regenerating periodontal tissue containing horse bone-derived nanoceramics and PCL and its manufacturing method | |
| Montanheiro et al. | Evaluation of cellulose nanocrystal addition on morphology, compression modulus and cytotoxicity of poly (3-hydroxybutyrate-co-3-hydroxyvalerate) scaffolds | |
| Wu et al. | Mechanical properties and permeability of porous chitosan–poly (p-dioxanone)/silk fibroin conduits used for peripheral nerve repair | |
| Do Amaral et al. | In vitro and in vivo response of composites based on chitosan, hydroxyapatite and collagen | |
| Subramanian et al. | Tunable mechanical properties of Mo3Se3-poly vinyl alcohol-based/silk fibroin-based nanowire ensure the regeneration mechanism in tenocytes derived from human bone marrow stem cells | |
| de Morais et al. | Polyurethane derived from castor oil monoacylglyceride (Ricinus communis) for bone defects reconstruction: characterization and in vivo testing | |
| CN114316162A (en) | Photo-crosslinking injectable nanofiber-hydrogel compound and preparation method and application thereof | |
| CN1216653C (en) | Method for preparing composite membrane for conducting tissue regeneration | |
| Yang et al. | Effect of Dehydrothermal Treatment on the Structure and Properties of a Collagen-Based Heterogeneous Bilayer Membrane | |
| Lee et al. | Photo-crosslinked gelatin methacryloyl hydrogel strengthened with calcium phosphate-based nanoparticles for early healing of rabbit calvarial defects | |
| US20120122219A1 (en) | Porous composite biomaterials and production method of the same | |
| CN115414527A (en) | Bionic bone-like composite scaffold, preparation method and application of bionic bone-like composite scaffold in rapid repair of bone defects | |
| KR101568146B1 (en) | Manufacturing method of ultra-high molecular weight poly glycol acid having biodegradable and implant having high stiffness and biodegradable manufacturing thereof | |
| Li et al. | Chitosan conduit for peripheral nerve regeneration | |
| CN111068108A (en) | Bone grafting bracket for repairing bone defect of long tube of four limbs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060215 Termination date: 20150316 |
|
| EXPY | Termination of patent right or utility model |